

Press release

Stockholm, Sweden, May 6, 2024

Mendus to participate in upcoming industry conferences

Mendus AB ("Mendus" publ; IMMU. ST), a biopharmaceutical company focused on immunotherapies targeting tumor recurrence, announces that it will participate in the following upcoming industry conferences in May:

CCBIO 12th Annual Symposium 2024

Bergen, Norway, May 14-15, 2024

Mendus researchers will attend and together with academic collaborators at the University of Bergen present immunomonitoring data from the ADVANCE II trial during the poster session of the Centre for Cancer Biomarkers (CCBIO) annual symposium.

[CCBIO's 12th Annual Symposium \(2024\) | Centre for Cancer Biomarkers CCBIO | UiB](#)

CIMT 21st Annual Meeting 2024

Mainz, Germany, May 15-17, 2024

Mendus researchers will attend and will present two abstracts at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT), the largest meeting focused on cancer immunotherapy research and development in Europe. Abstracts will be published on the conference website on May 13.

<https://www.meeting.cimt.eu/>

ALLG Scientific Meeting

Adelaide, Australia, May 21-24, 2024

Mendus supports and CMO Jeroen Rovers will participate in the Scientific Meeting organized by the Australasian Leukemia and Lymphoma Group (ALLG), in Adelaide, Australia. The ALLG biannual investigator meetings are working meetings of the membership of the group, not public conferences.

<https://www.allg.org.au/health-professionals/meetings-events/>

Oncode Accelerator Annual Event

Driebergen-Rijsenburg, The Netherlands, May 29-30, 2024

CEO Erik Manting will hold a presentation about the multidisciplinary approach to cancer vaccine development during the first Oncode Accelerator Annual Meeting. Mendus participates and is eligible for grant support for part of its research programs within the Oncode-PACT public-private partnership, which is supported by the Dutch National Growth Fund.

[Annual Event 'Collaborate to Demonstrate' | Oncode Accelerator](#)

Redeye Growth Day

Stockholm, Sweden, May 30, 2024

CEO Erik Manting will hold a company presentation during the Redeye Growth Day.

<https://www.redeye.se/events/981085/redeye-growth-day-2024?tab=attendingcompanies>

ASCO 2024 Annual Meeting

Chicago, US, May 31-June 4, 2024

CMO Jeroen Rovers will participate in the Annual Meeting of the American Society for Clinical Oncology (ASCO).

<https://conferences.asco.org/am/attend>

For more information, please contact:

Erik Manting, CEO

E-mail: ir@mendus.com

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. <https://www.mendus.com/>